Core Viewpoint - The study reveals a new mechanism by which lactate in the tumor microenvironment inhibits the anti-tumor function of natural killer (NK) cells through lactylation modification, providing new intervention targets and strategies to enhance NK cell cytotoxicity [1][3]. Group 1 - The research indicates that elevated levels of lysine lactylation (Kla) in NK cells are associated with impaired NAD metabolism, mitochondrial fragmentation, and reduced cytotoxicity [3]. - Supplementation with nicotinamide riboside (NR) and honokiol, a SIRT3 activator, enhances NK cell cytotoxicity by lowering intracellular Kla levels [3]. - The combination of NR and honokiol regulates Kla's effect on the protein kinase ROCK1, inhibiting the ROCK1-DRP1 signaling pathway to prevent mitochondrial fragmentation and restore NK cell activity against leukemia both in vivo and in vitro [3]. Group 2 - The study emphasizes that lactate-induced lactylation represents a new target for immunotherapy based on NK cells, aiming to enhance their tolerance to lactate within the tumor microenvironment [5]. - The research was conducted by a collaborative team from the University of Science and Technology of China and Fudan University, with key contributors including researchers Jin Jing, Yan Peidong, and Wang Dongyao [5].

Core Viewpoint - Beijing Ningmei Haowei Biotechnology Co., Ltd. has completed tens of millions in angel round financing to support research and industrialization in gene-edited cell therapy, focusing on clinical applications in precision anti-aging and chronic disease treatment such as diabetes [1][4] Group 1: Company Overview - Ningmei Haowei was founded in 2015 and aims to provide comprehensive precision medical and health management solutions from disease prevention and diagnosis to treatment, leveraging cutting-edge life science technologies [1] - The founding team consists of top domestic and international experts in life sciences and clinical medicine, with over a decade of experience in cell research and gene therapy, achieving multiple breakthrough research results [1] Group 2: Precision Medical Ecosystem - The company has established a precision medical ecosystem driven by "cell + gene" technology, covering the entire lifecycle [3] - Precision Anti-aging: Offers personalized anti-aging solutions through cell preparation and immune cell storage services based on leading global cell technology research and industrialization platforms [3] - Chronic Disease Treatment: Actively promotes stem cell therapy for major chronic diseases such as diabetes, cardiovascular diseases, and neurological disorders, collaborating with clinical institutions for efficacy evaluation to ensure treatment safety and durability [3] - Tumor Treatment: Focuses on gene-reprogrammed cell technology to create a comprehensive tumor cell treatment system, including personalized cell bank establishment, immune cell and stem cell differentiation preparation, and engineered cell line technology [3] Group 3: Quality Control and Future Plans - Ningmei Haowei has a strict quality control system ensuring safe cell sources with low immunogenicity and no potential infectious diseases or cancer risks, with cells stored in national authoritative institutions using top global storage equipment [4] - The company is equipped with GMP-grade independent laboratories and top-tier R&D, production, and quality inspection equipment, ensuring a sterile operating environment and automated, closed cell culture systems [4] - The recent financing will inject strong momentum into the company's R&D in cell therapy and gene editing technology, accelerating the transition of innovative therapies from laboratory research to clinical applications [4] - Future development plans include expanding the application scenarios of stem cell therapy in precision anti-aging and chronic disease treatment, continuously deepening the precision medical sector, and promoting the industrialization of cell therapy technology [4]

Core Viewpoint - Beijing Ningmeihao Wei Biotechnology Co., Ltd. has completed tens of millions in angel round financing to support research and industrialization in gene-edited cell therapy, focusing on clinical applications in precision anti-aging and chronic disease treatment [1][4] Group 1: Company Overview - Ningmeihao Wei was founded in 2015 and aims to provide comprehensive precision medical and health management solutions throughout the disease prevention, diagnosis, and treatment lifecycle [1][5] - The founding team consists of top domestic and international experts in life sciences and clinical medicine, with over a decade of experience in cell research and gene therapy [1] Group 2: Business Focus - The company focuses on a "cell + gene" dual-core strategy to build a precision medical ecosystem covering the entire lifecycle, including personalized anti-aging solutions and chronic disease treatments [1][2] - In chronic disease treatment, Ningmeihao Wei is advancing stem cell therapy applications for diabetes, cardiovascular diseases, and neurological disorders, collaborating with clinical institutions for efficacy evaluation [1][3] Group 3: Technology and Innovation - The company utilizes advanced technologies for stem cell preparation and NK cell production, adhering to pharmaceutical-grade cell production systems and quality management standards to ensure safety and efficacy [3][4] - Ningmeihao Wei has developed a dual technology platform of "pluripotent stem cell directed differentiation + gene editing" to explore treatment solutions for diabetes by repairing damaged pancreatic cells and restoring insulin secretion [3] Group 4: Quality Control and Future Plans - The company has a stringent quality control system ensuring low immunogenicity and safety of cell sources, with cells stored in top-tier facilities for long-term use [4] - Future development plans include expanding the application of stem cell therapy in precision anti-aging and chronic disease treatment, driving the industrialization of cell therapy technologies [4][5]